Bellicum Pharmaceuticals (BLCM) USPTO patents

Utility

Dual Controls for Therapeutic Cell Activation or Elimination

2 Mar 23

The technology relates in part to methods for controlling the activity or elimination of therapeutic cells using molecular switches that employ distinct heterodimerizer ligands, in conjunction with other multimeric ligands.

Joseph Henri Bayle, MyLinh Thi Duong, Matthew Robert Collinson-Pautz, Aaron Edward Foster, David Micheal Spencer

Filed: 31 Mar 21

Utility

Improved Formulations for Immune Cells

1 Sep 22

We disclose various improvements for compositions of T cells, including the use of lower levels of serum albumin and of cryoprotectants such as dimethyl sulfoxide.

Omar Baez, Devin Blass

Filed: 12 Aug 20

Utility

Methods for Controlled Elimination of Therapeutic Cells

28 Apr 22

The technology relates in part to methods for controlling elimination of therapeutic cells, for example, cells that express a chimeric antigen receptor.

David M. Spencer, Aaron Edward Foster, Joseph Henri Bayle, Kevin M. Slawin, Matthew R. Collinson-Pautz

Filed: 9 Jun 21

Utility

Psca Car-t Cells

3 Mar 22

The technology relates generally to the field of immunology and relates in part to T cell compositions and methods for treating diseases and disorders associated with the presence of tumor cells that express prostate stem cell antigen.

Paul WOODARD, Aaron Edward FOSTER, David Michael SPENCER, Olivia GARDNER, William GROSSMAN, Matthew Robert COLLINSON-PAUTZ, Annemarie MOSELEY

Filed: 12 Dec 19

Utility

T Cells with Suicide Switch

6 Jan 22

We disclose various improvements for compositions of genetically-modified T cells which include a suicide switch.

Xiaoou Linnette Zhou, Joanne Louise Shaw, Aaron Edward Foster, Madhavi Anumula, Matthew R. Collinson-Pautz

Filed: 29 Oct 19

Utility

Costimulation of Chimeric Antigen Receptors by MYD88 and CD40 Polypeptides

11 Nov 21

The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen.

David Spencer, Aaron Edward Foster, Kevin Slawin

Filed: 7 Dec 20

Utility

Methods to Augment or Alter Signal Transduction

20 May 21

The technology relates generally to the field of immunology and relates in part to compositions and methods for activating cells, including, for example T cells that express chimeric antigen receptors or recombinant TCRs, and reducing cytotoxicity, using chimeric polypeptides including MyD88 and signaling domains of receptor mediators of costimulation.

Joseph Henri Bayle, Wei-Chun Chang, Aaron Edward Foster, David Michael Spencer

Filed: 8 May 18

Utility

Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12

2 Mar 21

The technology relates generally to the field of immunology and relates in part to methods for activating cells, including for example T cells and T cells that express chimeric antigen receptors, using an inducible chimeric polypeptide including CD40, MyD88, or CD40 and MyD88 polypeptides.

Aaron Edward Foster, David Spencer, Matthew Robert Collinson-Pautz, Kevin Slawin

Filed: 13 Feb 15

Utility

Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptides

16 Feb 21

The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen.

David Spencer, Aaron Edward Foster, Kevin Slawin

Filed: 11 Feb 20

Utility

Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides

12 Jan 21

The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen.

David Spencer, Aaron Edward Foster, Kevin Slawin

Filed: 1 Sep 15

Utility

Methods for Enhancing and Maintaining Car-t Cell Efficacy

4 Nov 20

The technology relates generally to the field of immunology and relates in part to compositions and methods for activating T cells and other cells resulting in an immune response against a target antigen.

Aaron Edward Foster, David Michael Spencer

Filed: 6 Dec 18

Utility

Multimeric piperidine derivatives

30 Sep 20

Steven Toler, Slawomir Szymanski

Filed: 18 Dec 18

Utility

Costimulation of Chimeric Antigen Receptors by MYD88 and CD40 Polypeptides

29 Jul 20

The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen.

David Spencer, Aaron Edward Foster, Kevin Slawin

Filed: 10 Feb 20

Utility

Methods for Inducing Partial Apoptosis Using Caspase Polypeptides

22 Jul 20

The technology relates in part to methods for inducing partial apoptosis of cells that express an inducible caspase polypeptide.

Kevin Slawin, David Michael Spencer, Aaron Edward Foster

Filed: 2 Jan 20

Utility

Methods for inducing partial apoptosis using caspase polypeptides

6 Jan 20

The technology relates in part to methods for inducing partial apoptosis of cells that express an inducible caspase polypeptide.

Kevin Slawin, David Spencer, Aaron Edward Foster

Filed: 4 Feb 18